Today, the IFPMA release 'From resistance to resilience: What could the future antibiotic pipeline look like?'. Our analysis shows a more robust pipeline could reduce the potential burden on HICs by up to 63%, highlighting the desperate need for new incentives. Read more below.

"The West should be on a war footing for the next pandemic," writes Rasmus Bech Hansen, founder of Airfinity Covid-19 was not a once in a lifetime risk. Western allies need more than a global treaty to protect themselves from the next crisis. telegraph.co.uk/global-health/…

Don't miss this by Airfinity founder Rasmus Bech Hansen Excellent read and charts on why need to go further than a Pandemic Treaty if we are to properly protect ourselves from future threats. The good news: democracies did best with Covid... telegraph.co.uk/global-health/…

New analysis by Airfinity shows there has been a 300% rise in approved new #cancer treatments in the last two decades, with the US Cancer Moonshot Goal achievable by 2048. Click below to access the full findings on global cancer #disease burden. airfinity.com/articles/300-r…

Over 40 countries have reported at least one #infectious #disease resurgence that's 10-fold or more over their pre #pandemic baseline. Read Airfinity and Bloomberg' collaborative report on global disease resurgence below. bloomberg.com/news/features/…

Is avian influenza becoming less deadly? New analysis shows that case fatality rate (CFR) has dropped to a 33% average over the last 9 years, from 62% pre-2015. A lower CFR may signal that #H5N1 is becoming more suited to human-human infection. Reach out to learn more.

Has the pandemic fundamentally changed us or the pathogens which surround us? Our study, featured in The Telegraph, shows over 40 countries or territories have reported at least one infectious disease resurgence that’s 10-fold or more over their pre-pandemic baseline.

“There is a 27.5% chance of a COVID-like pandemic in the next 10 years." – Rasmus Bech Hansen, Founder and CEO of Airfinity, at the 2024 Copenhagen Democracy Summit. Watch the full session: youtube.com/watch?v=Pi4T8C…

As featured in the Financial Times today, Airfinity has reduced its sales projections for vaccines against Respiratory Syncytial Virus (#RSV) for older adults in the US from $4.7bn per year to $1.7bn by 2030. Reach out to find out more about our estimate or the burden of RSV.

With new CDC recommendations, RSV market's long-term value falls sharply in US: Airfinity fiercepharma.com/pharma/new-cdc…

Estimates from Airfinity suggest that the #us RSV vaccine market will drop by 2030 due to CDC #acip recommendations on #vaccination strategies. #vaccinenation #vaccine #rsv #globalhealth #market vaccinenation.org/global-health/…

Join our Science Summit 2025 Webinar: Data for Pandemic Preparedness: New approaches for medical countermeasure (MCM) delivery Live next Wednesday 18th September 2024, 3pm ET/ 8pm BST. Register for free through the UNGA Science Summit online portal below. sciencesummitunga.vfairs.com/en/registratio…

The cost of #Wegovy to prevent one stroke in the US is double what’s paid by Britain’s health service, reveals new analysis by Airfinity. Read our feature in Bloomberg to find out more. bloomberg.com/news/articles/…

What's new with bird flu and H5N1 pandemic prevention? Join me, Florian Krammer, Hanna Nohynek, and Bob Kadlec at this webinar to find out. October 10, 10 am ET, free registration at the link below! us02web.zoom.us/webinar/regist… Thanks to Airfinity & CSL Seqirus for organizing.

Watch our webinar: Countermeasure strategies to prevent an avian influenza pandemic here: youtu.be/QSDLvCuFOxo?si…

Interesting webinar hosted by Airfinity on From Science to Strategy: Making RSV, hMPV, and PIV vaccines work in the real world. The session discusses the challenges of integrating combinations vaccines, the impact of seasonality on rollout strategies and the global severe burden